TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9052452
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment for severe peptic ulcer haemorrhage
Study: 9052452
Drug: Maintenance acid-reducing
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance acid-reducing therapy
Study: 6669632
Drug: zopiclone 7.5
Normalized name: zopiclone 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: zopiclone 7.5 mg p.o. nightly for 21 days followed by placebo for 7 days
Study: 26298839
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n=39)
Study: 25112080
Drug: Mosapride citrate
Normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride citrate tablets (5 mg, 3 times a day for 4 weeks) in western medication control group
Study: 8787889
Drug: Imipenem plus
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem plus cilastatin (1 g each)
Study: 7652500
Drug: Meropenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1 g)
Study: 6337495
Drug: Dexamethasone (steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (steroid hormone)
Study: 30336703
Drug: XR-naltrexone (380
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR-naltrexone (380 mg initially, then monthly doses)
Study: 24002511
Drug: Response-guided chemotherapy
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response-guided chemotherapy (TAC × 8 or TAC-NX)
Study: 10787067
Drug: Continuous Hyperthermic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Hyperthermic Peritoneal Perfusion (CHPP) with saline solution containing 150 to 300 mg cisplatin and 30 to 60 mg mitomycin C for 60 minutes at 42.0 degrees C (n = 9)
Study: 10787067
Drug: Continuous Normothermic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Normothermic Peritoneal Perfusion (CNPP) with saline solution containing 150 to 300 mg cisplatin and 30 to 60 mg mitomycin C for 60 minutes at 37.0 degrees C (n = 7)
Study: 8982739
Drug: Ethinyl oestradiol
Normalized name: 17-ethinyl-3,17-oestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl oestradiol (50 micrograms daily for 14 days)
Study: 8982739
Drug: Oestrone sulphate
Normalized name: Oestrone
DrugBank: Estrone (DB00655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestrone sulphate (2.5 mg daily for 14 days)
Study: 17434437
Drug: CP‐675,206 immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP‐675,206 immunotherapy
Study: 11532477
Drug: Nafarelin acetate
Normalized name: Nafarelin Acetate
DrugBank: Nafarelin (DB00666)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nafarelin acetate (200 microg b.i.d. for 7 days followed by 200 microg daily)
Study: 9506565
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of weekly oral methotrexate and daily azathioprine (MTX/AZA)
Study: 9506565
Drug: Intravenous methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous methotrexate with leucovorin rescue (I.V. MTX)
Study: 7827349
Drug: Insulin-dependent diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetic patients with microalbuminuria
Study: 26578409
Drug: 1500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg/day arginyl-fructose
Study: 3302875
Drug: Ceftriaxone (CFX)
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone (CFX) 1 g/24 h im
Study: 3302875
Drug: Amikacin (AMK)
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin (AMK) 500 mg/24 h im
Study: 31992377
Drug: Betaine (BT)
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaine (BT) 0.6 g/kg DM without RPFA
Study: 31992377
Drug: Betaine (BT)
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaine (BT) 0.6 g/kg DM with RPFA
Study: 27138546
Drug: Rifampicin 10
Normalized name: Rifampicine
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 10 mg
Study: 27138546
Drug: Rifampicin 20
Normalized name: Rifampicin 20 mg/mL oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 20 mg
Study: 27138546
Drug: Rifampicin 100
Normalized name: Rifampicine
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 100 mg
Study: 19297116
Drug: Computer agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer agent explanation of consent form
Study: 17194911
Drug: XELOX (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX (intravenous oxaliplatin plus oral capecitabine; 3‐week cycle for eight cycles)
Study: 31240541
Drug: APAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: APAP therapy
Study: 31779693
Drug: Supervised progressive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised progressive strength training and oral protein supplement during hospitalization and at home 3 days/week for 4 weeks after discharge
Study: 31779693
Drug: Supervised progressive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised progressive strength training and oral protein supplement
Study: 25827594
Drug: Bolus whey
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus whey protein (WP; 20 g)
Study: 25827594
Drug: Low-dose leucine-enriched
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose leucine-enriched essential amino acids (LEAA; 3 g, 40% leucine)
Study: 21518557
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (rapid steroid reduction to 10 mg/d)
Study: 21518557
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard corticosteroid therapy)
Study: 10514159
Drug: Aspirin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (150 mg/day)
Study: 7557557
Drug: Picotamide (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide (450 mg/day)
Study: 8420815
Drug: Picotamide (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide (900 mg/day)
Study: 7557557
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus Picotamide (150 mg/day and 450 mg/day respectively)
Study: 30918121
Drug: Deferred PrEP
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred PrEP (DEF) with self-reported diagnosis of syphilis, rectal chlamydia (CT) or rectal gonorrhoea (GC) in the previous 12 months
Study: 30918121
Drug: Deferred PrEP
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred PrEP (DEF) lacking both syphilis/rectal CT/GC and multiple ncRAI partners
Study: 19473224
Drug: Individual art
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual art therapy sessions for 1 h/week (n = 20)
Study: 11829723
Drug: Deoxycholate or
Normalized name: ursodeoxycholate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deoxycholate or liposomal formulations of amphotericin B
Study: 2676609
Drug: Coumarin (1,2‐benzopyrone)
Normalized name: 3,3'-methylenebis(4-hydroxy-1,2-benzopyrone)
DrugBank: Coumarin (DB04665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumarin (1,2‐benzopyrone) daily oral dose of 50 mg
Study: 16792
Drug: Methyprylon 300
Normalized name: methyprylon 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyprylon 300 mg
Study: 29999197
Drug: Abametapir lotion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abametapir lotion, 0.74%
Study: 26033416
Drug: Parenteral oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral oestrogen
Study: 24531755
Drug: Vitamin C-rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C-rich apple juice (VCR) - 60 mg/L vitamin C and 510 mg catechin equivalent/L
Study: 24531755
Drug: Polyphenol-rich apple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol-rich apple juice (PR) - 22 mg/L vitamin C and 993 mg catechin equivalent/L
Study: 23094031
Drug: Caffeine (2*200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (2*200 mg)
Study: 20368553
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg every 2 weeks) plus interferon alfa-2a (9 MIU subcutaneously three times a week)
Study: 20368553
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus IFN (postprotocol therapy including a tyrosine kinase inhibitor)
Study: 20368553
Drug: IFN plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN plus placebo (postprotocol therapy including a tyrosine kinase inhibitor)
Study: 10372726
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (Nal‐Glu; 150 microg/kg) during midfollicular phase (MFP)
Study: 10372726
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (Nal‐Glu; 150 microg/kg) during late follicular phase (LFP)
Study: 10372726
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (Nal‐Glu; 150 microg/kg) during midluteal phase (MLP)
Study: 2115446
Drug: Rectal solution
Normalized name: Rectal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal solution (100 mg flecainide)
Study: 2115446
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution (100 mg flecainide)
Study: 2115446
Drug: Tablet (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet (100 mg flecainide)
Study: 7002205
Drug: Ritodrine (long
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritodrine (long infusion)
Study: 7002205
Drug: Ritodrine (short
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritodrine (short infusion)
Study: 7002205
Drug: Ritodrine (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritodrine (intramuscular injection)
Study: 7002205
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (bed rest and sedatives)
Study: 2687586
Drug: Oral pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pilocarpine
Study: 17729016
Drug: Modafinil (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100-400 mg/day or 200 mg/day)
Study: 12167574
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and 5-Fluorouracil chemotherapy (pulse regimen)
Study: 12167574
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and 5-Fluorouracil chemotherapy (continuous infusion regimen)
Study: 7712759
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of famotidine (1.7 mg/hr for 24 hrs)
Study: 7712759
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of famotidine (20 mg i.v. over 10 mins, every 12 hrs)
Study: 1506045
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of 16.5% immune serum globulin (ISG)
Study: 29851803
Drug: Sham laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham laser acupuncture (LA without laser output) plus conventional treatment
Study: 20606402
Drug: High-dose adecatumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adecatumumab (6 mg/kg)
Study: 20606402
Drug: Low-dose adecatumumab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adecatumumab (2 mg/kg)
Study: 17500020
Drug: Oral co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral co-trimoxazole for 3 months
Study: 15012690
Drug: Aspirin 200
Normalized name: aspirin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 200 mg daily for 8 weeks
Study: 15012690
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day for 8 weeks
Study: 11058789
Drug: Polymorphisms in
Normalized name: Murine MAb to polymorphic epithelial mucin, human milk fat globule 1
DrugBank: Pemtumomab (DB18563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorphisms in the alpha-2 macroglobulin gene (5 bp deletion and G/A point mutation)
Study: 11058789
Drug: Polymorphisms in
Normalized name: Murine MAb to polymorphic epithelial mucin, human milk fat globule 1
DrugBank: Pemtumomab (DB18563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorphisms in the alpha-2 macroglobulin gene (5 bp deletion and G/A point mutation) combined with APOE varepsilon4 genotype
Study: 9304162
Drug: No thrombolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No thrombolytic treatment
Study: 27874837
Drug: No-SP group
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-SP group (nonspiritual therapy)
Study: 24553973
Drug: Inhaled Budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Budesonide
Study: 12194619
Drug: Holding a
Normalized name: dextromethorphan hydrobromide Oral Lozenge [Hold DM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holding a weighted spoon (248 g)
Study: 12194619
Drug: Holding a
Normalized name: dextromethorphan hydrobromide Oral Lozenge [Hold DM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holding a built-up spoon (108 g)
Study: 12194619
Drug: Holding a
Normalized name: dextromethorphan hydrobromide Oral Lozenge [Hold DM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holding a built-up spoon while wearing a weighted wrist cuff (470 g)
Study: 7880662
Drug: Eltanolone 4
Normalized name: Eltanolone
DrugBank: Eltanolone (DB12308)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltanolone 4 mg ml‐1 administered at a rate of 300 ml h‐1
Study: 7880662
Drug: Eltanolone 4
Normalized name: Eltanolone
DrugBank: Eltanolone (DB12308)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltanolone 4 mg ml‐1 administered at a rate of 600 ml h‐1
Study: 7880662
Drug: Eltanolone 4
Normalized name: Eltanolone
DrugBank: Eltanolone (DB12308)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltanolone 4 mg ml‐1 administered at a rate of 1200 ml h‐1
Study: 31222771
Drug: Hyperinsulinaemia and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinaemia and insulin resistance (IR)
Study: 25130167
Drug: Kegel exercises
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kegel exercises with vaginal spheres, performed twice daily, 5 days/week for 6 months.
Study: 25130167
Drug: Kegel exercises
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kegel exercises without vaginal spheres (control group), performed twice daily, 5 days/week for 6 months.
Study: 22122814
Drug: Ibuprofen sodium
Normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen sodium dihydrate 400 mg
Study: 12162473
Drug: Conventional ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional ibuprofen 400 mg
Study: 19168461
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) or brain natriuretic peptide (BNP) as a diuretic
Study: 16765532
Drug: Intravenous L-alanyl-L-glutamine
Normalized name: L-Alanyl-L-glutamine
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-alanyl-L-glutamine 0.4 g/kg weight/day
Study: 11736859
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide (100 mg capsules) for 14 days
Study: 11736859
Drug: Intravenous etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous etoposide (50 mg) on day 1 or day 7
Study: 7848388
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms of fentanyl in 2 ml volume added to 0.5% bupivacaine
Study: 7848388
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms of fentanyl in 2 ml volume added to 0.5% bupivacaine
Study: 7848388
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of saline added to 0.5% bupivacaine
Study: 22812691
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 600 mg on days 1-3 and 1,200 mg on days 4-9, once daily
Study: 22812691
Drug: Oxcarbazepine (OXC)
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine (OXC) 300 mg on days 1-3 and 600 mg on days 4-9, twice daily
Study: 19419555
Drug: Amlexanox oral
Normalized name: amlexanox Oral Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlexanox oral adhesive pellicles
Study: 19419555
Drug: Amlexanox oral
Normalized name: amlexanox Oral Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlexanox oral adhesive tablets
Study: 17466972
Drug: 1-desamino-8-D-arginine-vasopressin administration
Normalized name: desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-desamino-8-D-arginine-vasopressin administration after water loading
Study: 11231774
Drug: Frequent aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Frequent aspirin use (>/=180 days per year)
Study: 9576406
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg/day)
Study: 7935702
Drug: Lovastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (40 mg orally twice daily)
Study: 3428345
Drug: Carvedilol 50
Normalized name: carvedilol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 50 mg capsule
Study: 3428345
Drug: Carvedilol 12.5
Normalized name: carvedilol 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 12.5 mg i.v.
Study: 3428345
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg capsule
Study: 3428345
Drug: Carvedilol 50
Normalized name: carvedilol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 50 mg suspension
Study: 23149081
Drug: Expectancy assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectancy assessment before first infusion
Study: 21681585
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg BGC20-1531
Study: 21681585
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg BGC20-1531
Study: 18365505
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections into internal anal sphincter
Study: 17052565
Drug: Acetaminophen extended
Normalized name: Acetaminophen Extended-Release
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen extended release 1,300 mg 3 times daily
Study: 17052565
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg 3 times daily
Study: 12747651
Drug: 0.3 ml
Normalized name: ethanol 0.3 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 ml (12.5 mg) triamcinolone acetonide intravitreally
Study: 12747651
Drug: 0.3 ml
Normalized name: ethanol 0.3 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 ml balanced salt solution after retrobulbar anesthesia
Study: 11149273
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa antagonists (abciximab, tirofiban, eptifibatide)
Study: 2867598
Drug: RP 40
Normalized name: RP-72
DrugBank: RP-72 (DB17156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP 40 749 (150 mg)
Study: 22476239
Drug: Lateral classic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral classic TAP block with 30 mL ropivacaine 0.375%
Study: 22476239
Drug: Dual 15
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dual 15 mL injections at the upper intercostal and lateral classic TAP plexuses
Study: 20573492
Drug: Antiwei (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiwei (6 g, twice daily for three days)
Study: 25824314
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment approaches
Study: 31109232
Drug: Traditional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatments (Control)
Study: 21651447
Drug: Pitavastatin calcium
Normalized name: PITAVASTATIN CALCIUM
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin calcium 1 mg/day
Study: 21651447
Drug: Pitavastatin calcium
Normalized name: PITAVASTATIN CALCIUM
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin calcium 2 mg/day
Study: 2156277
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg L-tryptophan administered intravenously over 20 min
Study: 2156277
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg L-tryptophan
Study: 21762225
Drug: TPI ASM8
Normalized name: TPI-ASM8
DrugBank: TPI-ASM8 (DB05572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPI ASM8 (4 mg b.i.d.)